Bain Capital Life Sciences Investors, LLC Nuvalent, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $370 Million
- Q4 2024
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 1,447,267 shares of NUVL stock, worth $107 Million. This represents 30.59% of its overall portfolio holdings.
Number of Shares
1,447,267
Previous 2,697,267
46.34%
Holding current value
$107 Million
Previous $276 Million
58.94%
% of portfolio
30.59%
Previous 49.52%
Shares
4 transactions
Others Institutions Holding NUVL
# of Institutions
231Shares Held
57.7MCall Options Held
834KPut Options Held
490K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.33 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$397 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$333 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$224 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$194 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.18B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...